In brief: Pharmanet Group, Metabolic Pharmaceuticals, Genetic Technologies
Friday, 24 June, 2005
The sale of Pharmanet Group's (ASX:PNO) wholly owned subsidiary Medical Products Group, to Advance Healthcare (ASX:AHG), has been completed. A 90-day convertible note has been issued by Advance to Pharmanet, satisfying the $400,000 settlement payment.
David Kenley, VP corporate development and one of the founders of Metabolic Pharmaceuticals (ASX:MBP), has resigned from the company to become CEO of Xceed Biotechnology (ASX:XBL). Kenley will leave Metabolic on 1 July and join Xceed in mid July.
Henry Bosch has been appointed as a non-executive director of Genetic Technologies (ASX:GTG).
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...